DGK-ι Activators are a set of compounds that enhance the protein's activity through multifaceted biochemical mechanisms. Phorbol 12-myristate 13-acetate (PMA) and Bryostatin 1 act as PKC activators, which indirectly potentiate DGK-ι by modulating the enzyme's phosphorylation and interaction with its lipid substrate, diacylglycerol (DAG). Sphingosine-1-phosphate and Ceramide, by influencing sphingolipid and glycerolipid metabolism, respectively, can shift the balance of cellular lipids, potentially increasing the availability of DAG for DGK-ι to convert into phosphatidic acid (PA), a critical molecule in membrane biosynthesis and signaling pathways. Arachidonic acid, released from membrane phospholipids, also adjuststhe DAG pool, indirectly stimulating DGK-ι's activity. Forskolin and Dibutyryl-cAMP (db-cAMP), by increasing cAMP levels, initiate a cascade involving PKA activation, which might lead to the phosphorylation and subsequent activation of DGK-ι. Additionally, Ionomycin, by raising intracellular calcium levels, can activate DGK-ι due to its calcium-dependent regulatory mechanisms. Retinoic acid and 1,2-Dioctanoyl-sn-glycerol (DiC8) modulate DGK-ι's activity by affecting the turnover of its substrate, with DiC8 mimicking DAG to potentially accelerate the catalytic conversion to PA.
Lithium chloride and Calyculin A contribute to the activation of DGK-ι through their effects on the phosphoinositide pathway and protein phosphorylation states, respectively. Lithium chloride maintains higher levels of DAG by inhibiting inositol monophosphatase, leading to potential DGK-ι activation due to increased substrate availability. Calyculin A sustains the phosphorylation of proteins, which could result in the enhanced activity of DGK-ι through phosphorylation-dependent regulatory mechanisms. Collectively, these chemical activators orchestrate a network of signaling events that converge on DGK-ι, facilitating its role in synthesizing PA, without necessitating the upregulation of its expression or direct activation. Each activator, through its distinct action on various signaling pathways, ensures that DGK-ι function is augmented, contributing to the complex regulation of lipid-mediated signal transduction.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA, as an activator of protein kinase C (PKC), can indirectly enhance DGK-ι activity. PKC phosphorylation can lead to activation of DGK-ι, which is responsible for the conversion of diacylglycerol (DAG) to phosphatidic acid (PA), a key step in signal transduction and membrane biosynthesis. | ||||||
1,2-Dioctanoyl-sn-glycerol | 60514-48-9 | sc-202397 sc-202397A | 10 mg 50 mg | $46.00 $249.00 | 2 | |
DiC8, a DAG analog, can act as a DGK-ι activator by mimicking the substrate of DGK-ι, thereby potentially increasing its catalytic activity towards the synthesis of PA. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid can modulate lipid signaling pathways, indirectly enhancing DGK-ι activity by influencing the turnover of DAG, its substrate, in lipid signaling cascades. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P is a bioactive lipid that may enhance DGK-ι activity indirectly by modulating sphingolipid metabolism, which is closely linked to glycerolipid metabolism, thereby affecting the availability of DAG for DGK-ι to convert to PA. | ||||||
C2 Ceramide | 3102-57-6 | sc-201375 sc-201375A | 5 mg 25 mg | $77.00 $316.00 | 12 | |
Ceramide can influence sphingolipid metabolism, indirectly affecting DGK-ι activity by altering the balance between ceramide and DAG levels in the cell, with potential increases in DAG serving as a substrate for DGK-ι. | ||||||
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $90.00 $235.00 $4243.00 | 9 | |
Arachidonic acid can serve as a lipid messenger itself and its release from membrane phospholipids can modulate DGK-ι by altering the pool of DAG which is the substrate for DGK-ι. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium influences the phosphoinositide signaling pathway by inhibiting inositol monophosphatase, potentially increasing DAG levels and thereby indirectly enhancing DGK-ι activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin elevates intracellular cAMP levels, which can activate PKA. PKA phosphorylation can modulate DGK-ι activity by influencing its interaction with DAG and other regulatory proteins. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin is a calcium ionophore that can increase intracellular calcium levels, which may indirectly activate DGK-ι by altering its calcium-dependent regulatory mechanisms. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $240.00 | 9 | |
Bryostatin 1, as a PKC modulator, can enhance DGK-ι activity by influencing PKC-mediated regulatory pathways that affect DGK-ι's activity and localization. | ||||||